Market research
MDNAF Medicenna Therapeutics Corp
OTCQX USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 2.1
Profile
Instrument facts
- Exchange
- OTCQX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 2.1
About
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Research context
Medicenna Therapeutics Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the MDNAF discussion.
No comments yet
Start a focused discussion about MDNAF.